Rethinking clinical strategy for treating dry eye disease
Realizing Cyclosporin’s Untapped Potential
“The strong case for NOV03”
“Smaller drops, bigger impact”
Christian Roesky discusses the underserved condition of dry eye disease
Overcoming the Challenges of Ophthalmic Delivery Using Aqueous-Free Technology: Redefining Dry Eye Disease
The Pathophysiology of Dry Eye Disease
Inflammation in Dry Eye Disease
Redefining the Eyedrop
Eye on the Prize: Drug Delivery Advances to Fuel Ophthalmic Drug Market
Fatty acid composition and lipid hydroperoxide in the meibum of patients with MGD
